Research Summary
Dr. Resar's studies molecular mechanisms leading to cancer, blood diseases, sickle cell anemia, hemophilia and other coagulopathies. Her research focuses on the HMG-I/Y gene family, which is widely overexpressed and functions as oncogenes in human cancers. Her laboratory recently developed transgenic mice overexpressing HMG-I; all mice develop aggressive lymphoid malignancy similar to leukemia and lymphoma in humans. Her studies also demonstrate that this gene is overexpressed in human lymphoid and other malignancies. Translational studies are underway to determine if overexpression of HMG-I is a marker for more aggressive human cancers. Resar's long-term goal is to develop more rational therapies that interfere with HMG-I/Y function in neoplastic transformation.
Lab
Lab Website: Linda Smith-Resar Lab
Selected Publications
View all on PubMed
Savage, W.J.; DeRusso, P.A.; Resar, L.M.; Chen, A.R.; Higman, M.A.; Loeb, D.M.; Jones, R.J.; Brodsky, R.A. Treatment of hepatitis-associated aplastic anemia with high-dose cyclophosphamide. Pediatr Blood Cancer. 2007 Dec;49(7):947-951
Tesfaye, A.; Di Cello, F.; Hillion, J.; Ronnett, B.M.; Elbahloul, O.; Ashfaq, R.; Dhara, S.; Prochownik, E.; Tworkoski, K.; Reeves, R.; Roden, R.; Ellenson, L.H.; Huso, D.L.; Resar, L.M. The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis. Cancer Res. 2007 May 1;67(9):3998-4004
Di Cello, F.; Hillion, J.; Hristov, A.; Wood, L.J.; Mukherjee, M.; Schuldenfrei, A.; Kowalski, J.; Bhattacharya, R.; Ashfaq, R.; Resar, L.M. HMGA2 participates in transformation in human lung cancer. Mol Cancer Res. 2008 May;6(5):743-750
Di Cello, F.; Hillion, J.; Kowalski, J.; Ronnett, B.M.; Aderinto, A.; Huso, D.L.; Resar, L.M. Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts. Mol Cancer Ther. 2008 Jul;7(7):2090-2095
Hillion, J.; Dhara, S.; Sumter, T.F.; Mukherjee, M.; Di Cello, F.; Belton, A.; Turkson, J.; Jaganathan, S.; Cheng, L.; Ye, Z.; Jove, R.; Aplan, P.; Lin, Y.W.; Wertzler, K.; Reeves, R.; Elbahlouh, O.; Kowalski, J.; Bhattacharya, R.; Resar, L.M. The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an Achilles heel for hematopoietic malignancies Cancer Res. 2008 Dec 15;68(24):10121-10127
Hines, P.; Dover, G.J.; Resar, L.M. Pulsed-dosing with oral sodium phenylbutyrate increases hemoglobin F in a patient with sickle cell anemia. Pediatr Blood Cancer. 2008 Feb;50(2):357-359
Hillion, J.; Wood, L.J.; Mukherjee, M.; Bhattacharya, R.; Di Cello, F.; Kowalski, J.; Elbahloul, O.; Segal, J.; Poirier, J.; Rudin, C.M.; Dhara, S.; Belton, A.; Joseph, B.; Zucker, S.; Resar, L.M. Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer. Mol Cancer Res. 2009 Nov;7(11):1803-1812
Hristov, A.C.; Cope, L.; Reyes, M.D.; Singh, M.; Iacobuzio-Donahue, C.; Maitra, A.; Resar, L.M. HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod Pathol. 2009 Jan;22(1):43-49
Hristov, A.C.; Cope, L.; Di Cello, F.; Reyes, M.D.; Singh, M.; Hillion, J.A.; Belton, A.; Joseph, B.; Schuldenfrei, A.; Iacobuzio-Donahue, C.A.; Maitra, A.; Resar, L.M. HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. Mod Pathol. 2010 Jan;23(1):98-104
Mazaheri, P.; Nadkarni, G.; Lowe, E.; Hines, P.; Vuica, M.; Griffin, M.; Resar, L.M. Ghosal hematodiaphyseal dysplasia: a rare cause of a myelophthisic anemia. Pediatr Blood Cancer. 2010 Dec 1;55(6):1187-1190
Resar, L.M. The high mobility group A1 gene: transforming inflammatory signals into cancer? Cancer Res. 2010 Jan 15;70(2):436-439
Karp, J.E.; Smith, B.D.; Resar, L.S.; Greer, J.M.; Blackford, A.; Zhao, M.; Moton-Nelson, D.; Alino, K.; Levis, M.J.; Gore, S.D.; Joseph, B.; Carraway, H.; McDevitt, M.A.; Bagain, L.; Mackey, K.; Briel, J.; Doyle, L.A.; Wright, J.J.; Rudek, M.A. Phase I and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood. 2011 Jan 14;Epub 1/18/11
Patient Ratings & Comments
The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
Comments